Improving Outcome in Gastrointestinal and Hepatopancreaticobiliary Surgical Oncology by Preoperative Risk Assessment and Optimization of Perioperative Care by Jongen, Audrey C.H.M. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
Improving Outcome in Gastrointestinal and
Hepatopancreaticobiliary Surgical Oncology by
Preoperative Risk Assessment and Optimization of
Perioperative Care
Audrey C.H.M. Jongen, Victor van Woerden,
Jeroen L.A. van Vugt, Patrick A. de Hoogt,
Elisabeth M.L. de Wijkerslooth de Weerdesteijn,
Juul J.W. Tegels, Nicole D. Bouvy and
Jan H.M.B. Stoot
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64775
Provisional chapter
Improving Outcome in Gastrointestinal and
Preoperative Risk Assess ent and pti ization of
Perioperative Care
Audrey C.H.M. Jongen†, Victor van Woerden†,
Jeroen L.A. van Vugt, Patrick A. de Hoogt,
Elisabeth M.L. de Wijkerslooth de Weerdesteijn,
Juul J.W. Tegels, Nicole D. Bouvy and
Jan H.M.B. Stoot
Additional information is available at the end of the chapter
Abstract
This chapter discusses the most important challenges in the perioperative phase of the
oncology patient undergoing surgery of the gastrointestinal tract. Because of the aging
population, the surgeon is ever more confronted with frail patients at risk for an adverse
surgical outcome. The chapter therefore reviews factors contributing to an impaired
postoperative outcome such as sarcopenia, frailty, cachexia, and malnutrition and gives
an  insight  into  their  pathophysiology.  Next,  it  provides  an  overview of  validated
preoperative classification systems to identify the patients at risk for surgical compli‐
cations. Furthermore, it discusses the most essential recommendations of standardized
care for patients undergoing hepatopancreaticobiliary, gastric, and colorectal surgery.
Special attention is paid to the use of clinical pathways in the perioperative phase that
are aimed at a multimodal approach of reducing surgical morbidity by lowering the
perioperative  physiological  and psychological  stress.  Recent  literature  is  discussed
regarding care in the intensive care unit, and the final paragraph focuses on improving
postoperative  outcome  by  means  of  prehabilitation  or  exercise  as  well  as  dietary
interventions and optimized nutrition.
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1. Introduction in surgical oncology of the abdomen
1.1. General introduction
Cancers of the gastrointestinal (GI) and hepatopancreaticobiliary (HPB) tract entail some of
the most prevalent, as well as some of the most lethal, cancers worldwide [1]. Surgery for
cancer of the digestive tract involves extensive and complex procedures and is associated with
high complication rates [2]. In the past decades, however, the clinical outcome of patients
undergoing surgery for gastrointestinal malignancies has improved significantly. Besides the
changes in surgical technique, such as the introduction of minimally invasive surgery and the
implementation of novel medical devices, the anesthetic and perioperative care have also
evolved [3]. Patients operated with laparoscopic techniques showed a reduction in various
inflammatory responses and improved immune function when compared to patients
undergoing open surgery in several randomized clinical trials. These studies, however, did
not take into account the change in perioperative care that was brought about by the faster
recovery following laparoscopic surgery. More recent randomized controlled trials standar‐
dized care for both arms and found better outcomes for patients treated with laparoscopy and
clinical care pathways, in most [4, 5], but not in all cases [6].
Many important factors have been described that influence the surgical outcome of the surgical
oncology patient population. These factors are present in a wide range of surgical patients, but
particularly high rates have been described in the elderly population. Aging is accompanied
by high prevalence of comorbidities and a decreased functional reserve, all of which can
contribute to an increased risk for complications such as delirium, pressure ulcers, infection,
functional decline, and other surgery‐specific complications. While the increased quality of
care is advantageous for the general oncological population, improvement in outcome for
elderly patients has remained relatively limited [7, 8]. This is a worrisome fact, as the aging
Western population leads to an increase of elderly people diagnosed with cancer and, conse‐
quently, more elderly people in need of surgical care. Many of the currently available treatment
guidelines for surgical oncology patients are based on clinical data from a patient population
with a relative low number of old and more frail patients. Therefore, in order to further improve
outcomes also for our most vulnerable patients, identifying those at highest risk of poor
outcome is of paramount importance.
The need for tools that provide insight in our patients’ health status prior to undergoing
surgery has become overt. It has been shown that functional compromise, defined by several
conditions such as fatigue, sarcopenia, cachexia, malnutrition, vulnerability, and frailty, has a
major impact on the risk of the development of complications and on postoperative outcome
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in general. These conditions show strong overlap in several clinical features, which make strict
separation of these syndromes rather difficult.
Several authors have described questionnaires and tests that allow surgeons to identify the
patients at high risk. With these tools, patients that are prone to developing complications can
be selected for a broad range of intervention types that are aimed at optimizing the condition
of the surgical patient and consequently to improve postoperative outcome. To date, a wide
variety of validated risk assessment tools have been described. Some of those have already
successfully been introduced into clinical practice, such as the ASA (American Society of
Anesthesiologist) classification, the Surgical Outcome Risk Tool (SORT) [9], and the Surgical
Risk Calculator from the American College of Surgeons [10]. Many other, more specific scoring
systems or tests have been designed to assess frailty (Comprehensive Geriatric Assessment
[11], Fried Frailty Phenotype [12], timed “up and go” test [13], Groningen Frailty Index [14]),
or nutritional state (Short Nutritional Assessment Questionnaire (SNAQ) [15], Malnutrition
Universal Screening Tool (MUST)) [12, 16]. These assessment tools are designed to identify the
patients at high risk for perioperative complications and adverse outcomes. Moreover, these
may help the physician in the selection of patients that may benefit from “prehabilitation” and
nutritional and other interventions.
During the course of the chapter, the most important challenges for the care of the gastroin‐
testinal surgical oncology patient will be discussed. Special attention will be paid to identifying
and treating the patient at highest risk of adverse outcome. A short overview of the different
tumors of the gastrointestinal tract will be provided based on tumor location, as each of these
types of cancer are defined by specific characteristics. Furthermore, the most important
perioperative considerations are discussed, as well as the most common complications and
their management.
1.2. Types of cancer
1.2.1. Esophageal cancer
Esophageal cancer is the eighth most prevalent cancer and the sixth most frequent cause of
cancer‐related death worldwide. Global incidence is threefold higher in men as compared to
women. With a mortality:incidence ratio of 0.88 esophageal cancer has a poor prognosis, which
resulted in 400,000 deaths in 2012 [1]. Over 95% of esophageal cancers consist of squamous cell
(SCC) and adenocarcinomas. Incidence of SCC is especially high in Iran and Asia (the so‐called
esophageal cancer belt) [3]. In Western countries, incidence of adenocarcinomas has increased
substantially over the past decades, of which the most frequently affected sites are the
esophagogastric junction (ECJ) and the gastric cardia [17–20]. Alcohol consumption and
smoking are the main risk factors in the etiology of esophageal cancer [21–24]. Others are
Barrett’s esophagus, gastroesophageal reflux disease, poor diet and high body mass index [24].
Currently, radical surgical resection is considered the standard treatment for resectable
esophageal carcinoma (T1‐3N0‐3M0) [25, 26]. Proximal and mid‐esophageal tumors are
approached transthoracically, distal tumors are resected through either transthoracic or
transhiatal approach. Neoadjuvant chemoradiation has shown to improve local control and
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survival and is commonly performed [27–30]. In case of unresectable carcinomas or contrain‐
dications for surgery, chemoradiation can be performed depending on the patient’s condition
[31–33].
1.2.2. Gastric cancer
Gastric cancer is the fifth most prevalent cancer and the third most common cause of cancer
related death worldwide. About half of all cases occur in eastern Asia [1]. There are two types
of gastric adenocarcinoma: the intestinal and the diffuse type. Both can be induced by
Helicobacter pylori infection, the primary cause of gastric cancer [34]. Gastric ulcers, adenoma‐
tous polyps and intestinal metaplasia are known precursor lesions in the intestinal type gastric
cancer, while no clear precursor lesions can be indicated for the diffuse type [35]. Smoking and
alcohol consumption are important risk factors, as well as dietary factors such as high salt and
low vegetable intake [36, 37].
In Western countries, gastric cancer is often diagnosed at an advanced stage [38, 39]. Proximal
tumors are known to be more aggressive and to have a worse prognosis compared to distal
gastric cancers [40]. Curative treatment is not possible in case of distant metastasis [41], leaving
only 50% of patients eligible for curative surgery. Partial or total gastrectomy is performed
depending on tumor location, clinical stage, and histological type. The extent of lymphade‐
nectomy remains a topic of debate [42, 43]. Tumors of the esophagocardial junction (ECJ) and
cardia are treated, like esophageal cancers, with neoadjuvant chemoradiation. To date, there
is no clear consensus in literature regarding (neo‐)adjuvant therapy for noncardia gastric
cancers. It has been shown, however, that perioperative chemotherapy significantly improves
survival [44, 45].
1.2.3. Cancer in the liver
Most of the malignant lesions that are diagnosed in the liver are metastases from primary
tumors that are located in other organs. The majority of those metastases are of colonic or rectal
origin, so‐called colorectal liver metastasis (CRLM). The liver is the first organ in which
colorectal tumors metastasize due to the venous drainage of the gastrointestinal tract via the
portal vein. Radical surgical resection is the established curative treatment for CRLM.
Partial liver resections can be performed through anatomic or nonanatomic approach,
depending on tumor localization and its relation to the portal vein, hepatic vein, and hepatic
artery. Important considerations for performing liver surgery for CRLM are to ensure sufficient
residual liver volume after resection and to plan a radical resection. Tumor size, the number
of metastases, the patient’s age, narrow resection margin, extrahepatic disease, synchronicity,
and primary tumor stage can all be taken into consideration but are no absolute contraindi‐
cations for performing a partial liver resection for CRLM. In case, a radical surgical resection
cannot be performed, radiofrequent and microwave ablation techniques and stereotactic
radiotherapy can be considered as alternative treatment.
In the case of CRLM, the majority of the patients receive (neo‐)adjuvant chemotherapy because
of the presence of metastatic disease. Chemotherapy can be used for down staging of the
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tumors and to increase resectability. Because of its negative effects on the liver parenchyma, a
larger residual liver volume must be ensured if chemotherapy was administered preopera‐
tively.
Primary liver cancer occurs in the liver as well, usually as hepatocellular carcinoma (HCC).
HCC has a mortality:incidence ratio of 0.95 liver cancer is the second most frequent cause of
cancer death in the world, resulting in approximately 745,000 deaths in 2012 [1]. It is the sixth
most prevalent cancer worldwide and incidence rates are about two‐ to threefold higher in
men compared to women [1, 46]. Chronic liver disease (i.e., chronic hepatitis B or C infection,
hereditary hemochromatosis, nonalcoholic fatty liver disease) and cirrhosis are associated with
increased risk of hepatocellular carcinoma (HCC) [46–48]. Echographic surveillance in patients
at increased risk can detect HCC at an earlier stage [49]. Depending on performance status,
Child‐Pugh classification and clinical stage, a partial liver resection or liver transplantation
may be indicated [48]. Up to 80% of liver volume can be resected, provided the quality of the
residual volume is high enough for regeneration and to avoid liver failure. In short, postop‐
erative morbidity and mortality rates are only acceptable in patients with Child Pugh A and
without portal hypertension. Therefore, due to liver dysfunction, most patients are ineligible
for surgical treatment. Treatment options for unresectable HCC include radiofrequent ablation
(RFA), percutaneous ethanol injection (PEI), transcatheter chemo‐embolization (TACE),
stereotactic radiotherapy, and systemic chemotherapy [50–55].
1.2.4. Pancreatic cancer
Despite diagnostic and therapeutic advances, pancreatic cancer has a very poor prognosis. It
is the twelfth most prevalent cancer worldwide yet the seventh most frequent cause of cancer‐
related death (M:I ratio 0.98) [1]. The majority of cases occur in western countries (possibly due
to underdiagnosis in less developed regions) [1]. Smoking is a main risk factor associated with
increased risk of pancreatic cancer [56, 57], as well as chronic pancreatitis [58, 59], high body
mass index [60, 61], and having a first‐degree relative with pancreatic cancer [62–64]. The
majority of tumors are ductal adenocarcinomas and over 95% arises from the exocrine elements
of the pancreas. Surgical resection is considered the only potentially curative treatment,
however only about 15–20% of patients are eligible for a pancreaticoduodenectomy (Whipple)
[65]. Prognosis is poor even in those patients; 5‐year survival is about 10% in case of node‐
positive and about 25–30% in node‐negative disease [66–68]. Tumor characteristics are the only
significant prognostic factor influencing survival after surgery [69]. Adjuvant chemotherapy
has proven to improve disease free survival [70–72]. Neo‐adjuvant chemoradiation, as this may
improve resectability of the tumor, decreases recurrence rates [73–76]. In a palliative setting,
chemotherapy and biliodigestive bypass surgery can be useful [77–81].
1.2.5. Cancers of the biliary tract
Cancers of the gallbladder and of the bile duct are less common, however, highly fatal as
they are often diagnosed at an advanced stage. Gallbladder carcinoma accounts for around
1.3% of cancer incidence worldwide and is one of the few malignancies that is more com‐
mon in females than in males [1, 82, 83]. Statistics on cholangiocarcinoma are less accurate
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as intrahepatic cholangiocarcinomas are often included in the primary liver cancers. Gall‐
stone disease, gallbladder polyps, congenital biliary cysts, anomalous pancreaticobiliary
junction, and chronic cholecystitis are predisposing factors for developing gallbladder can‐
cer. Risk factors for cholangiocarcinoma include primary sclerosing cholangitis, choledo‐
chal cysts, chronic hepatolithiasis (recurrent pyogenic cholangitis), and chronic liver
disease.
Resectability is dependent on the degree of infiltration into the proximal bileducts and liver
tissue, the absence of distant metastasis and involvement of the hepatic artery and/or portal
vein and the expected residual liver tissue volume [84, 85]. To ensure radical (R0) resection
of these aggressive tumors, extensive liver resection and resection of other neighboring or‐
gans is sometimes necessary [86–88]. The radicality of the resection is the most important
prognostic factor [89, 90]. The adequate surgical approach is selected based on tumor loca‐
tion and extent of tumor ingrowth. A Whipple procedure (pancreaticoduodenectomy) may
be indicated in case of a distal cholangiocarcinoma. In the preoperative setting, biliary
drainage and/or embolization of the portal vein may be indicated [91–94]. The role of
(neo‐)adjuvant chemo‐ and radiotherapy remains controversial and is not part of standard
treatment [88, 95–97].
1.2.6. Colorectal cancer
Colorectal cancer (CRC) is the second most prevalent cancer in women, and the third most
prevalent in men worldwide. The majority of cases occur in the Western world, although in
recent years an increase of CRC incidence has been observed in developing countries as well,
which is likely to be a consequence of the adoption of Western lifestyle and diet. CRC resulted
in 694,000 deaths in 2012, which makes it the fourth most frequent cause of cancer death [1].
In developed countries, the incidence and mortality have decreased over the past decades,
which is largely attributable to the implementation of better screening tools and national
screening programs [98–100].
Age, adenomatous polyps, genetic factors (FAP, HNPCC), inflammatory bowel disease, history
of abdominal radiotherapy, and lifestyle are the main factors associated with increased risk of
colorectal cancer [101–106]. The vast majority of colorectal cancers are adenocarcinomas. All
tumors originate from adenomas or flat dysplasia. Tumors of the right colon are more polypoid
shaped as opposed to the annular tumors in the left colon. The prognosis for both tumor
locations is, however, similar [107]. Radical resection remains the cornerstone of curative
treatment. The surgical approach of choice depends on tumor location and size (i.e., right/left
hemicolectomy, low anterior resection, total mesorectal excision, or abdominoperioneal
resection). In case of locally advanced (T4) tumors, en‐bloc multivisceral resection is advised
[108, 109]. Local recurrence is more common in rectal cancer due to difficulty in obtaining
adequate resection margins. In rectal cancer, neoadjuvant radiotherapy or chemoradiation
may be indicated depending on disease stage. Neoadjuvant chemoradiation is also usually
considered in case of locally advanced colon cancer [108]. Adjuvant chemotherapy has only
proven to be beneficial for lymph node positive colon cancer.
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2. Current challenges in gastrointestinal, hepatobiliary, and pancreatic
surgical oncology
2.1. Frail elderly
With the aging of the population, patients undergoing surgery for gastrointestinal and
hepatobiliary and pancreatic cancers are also becoming older: one of every three cancers is
diagnosed in patients aged 65 years or older. A more worrying fact, however, is that the
majority of cancer‐related deaths occur in this group of patients [110]. Older patients are at
increased risk for perioperative complications [111], which may lead to prolonged hospital
stay, decreased quality of life and independency, increased disability and health‐care costs,
and increased mortality [112]. Nevertheless, carefully selected patients seem to benefit from
surgery in the long‐term [113]. Therefore, preoperative risk assessment, and multimodal
perioperative care for elderly patients remain of paramount importance in the light of changing
patient demographics [114]. Various risk classification systems, such as the American Society
for Anesthesiologists (ASA) classification, Charlson Comorbidity Index, and the Eastern
Cooperative Oncology Group (ECOG) performance status, have been developed to categorize
patients’ preoperative condition [115–117]. However, many of these classifications are inaccu‐
rate; they are subjective or focus on a single organ system [118]. The ASA classification for
instance, shows large intraobserver variability [116, 119], and lacks specificity for cancer
patients, who are known to have an altered metabolism that may affect ASA‐score.
Factors contributing to an impaired postoperative outcome for vulnerable (elderly) patients
are frequently referred to as “frailty.” Frailty has gained attention as a risk factor for adverse
outcome after surgery over the past decades. Screening for and the assessment of frailty can
aid risk assessment and therefore facilitate the decision making process for both patients and
physicians. The concept of frailty was defined as a biologic syndrome, characterized by a
decreased reserve and resistance to stressors [12, 109]. It incorporates a number of areas of
functioning, including weight loss, muscle weakness (e.g., grip strength), slowness, low
activity, and increased disability [12]. Increased 6‐month mortality was observed in frail
individuals in a study of patients who underwent major surgery (i.e., procedures that required
standard ICU admission) [120]. Geriatric markers for frailty (e.g., cognitive function, poor
nutritional status, falls, depressed mood, and anemia) were predictive for adverse outcome in
this study [120]. Furthermore, increased complication rate and length of stay were observed
in frail patients who underwent elective surgery [121]. Finally, frailty was shown to be
associated with increased surgical complications, postoperative mortality, health care costs,
and length of stay [118, 120, 122].
2.2. Sarcopenia and cachexia
A modifiable, hallmark sign of frailty is sarcopenia, a geriatric term for the involuntary loss of
skeletal muscle mass and density [123–125]. The prevalence of sarcopenia increases with age;
from 9% at 45 years to 64% at 85 years in healthy ambulatory individuals [126]. This condition
is characterized by a loss of skeletal muscle mass and strength [127], leading to physical
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impairment and disability in geriatric populations [128, 129]. Multiple studies have shown an
association between the presence of sarcopenia and adverse outcome after surgery. For
instance, following surgery for colorectal liver metastases, sarcopenia negatively affected
short‐term outcome with increased morbidity and mortality rates In a study published in 2011
[130]. Sarcopenia also negatively influenced long‐term outcome in patients who underwent
surgery for pancreatic adenocarcinoma (i.e., 3‐year survival), as well as for patients undergoing
surgery for colorectal liver metastases (i.e., 5‐year disease free and overall survival) [131, 132].
Similar studies found an unusually high prevalence of sarcopenia (57.7% of 180 patients) in
Western gastric cancer patients [133]. However, this study did not find any association with
adverse outcomes in patients with sarcopenia. Another recent study in Asian gastric cancer
patients described a much lower prevalence of sarcopenia (12.5% of 255 patients). This study
combined CT‐scan measurements with hand‐grip strength and get‐up‐and‐go tests to define
sarcopenia. In this study, sarcopenia was found to be an independent risk factor for postop‐
erative complications [134]. Besides sarcopenia, older cancer patients may also suffer from
cancer induced cachexia, a clinical condition leading to skeletal muscle loss with or without
the loss of adipose tissue due to anorexia (resulting from e.g. metabolic changes) and malnu‐
trition (resulting from e.g. (chemotherapy induced) nausea and loss of appetite) [135, 136]. It
is estimated that cachexia is the cause of up to 30% of cancer related deaths [137, 138]. Sarco‐
penia and cachexia are therefore separate but overlapping entities, with different pathways
that both lead to skeletal muscle wasting [139]. The assessment of sarcopenia will be elucidated
further in the third paragraph.
2.3. Body composition and chemotherapy
Although surgery remains the cornerstone of curative cancer treatment in all gastrointestinal
and hepatopancreatobiliary malignancies, a substantial part of patients is treated with
chemotherapy [29, 140]. This could be either in a neoadjuvant setting to reduce the tumor load,
as well as in an adjuvant or palliative setting in patients with locally advanced/metastasized
disease or recurrence, respectively.
A recent report described that skeletal muscle loss during neoadjuvant chemotherapy is
associated with poor short‐term outcome in esophageal cancer patients [141]. Two other
studies did not find an association with overall (long‐term) survival [142, 143]. In a study
among breast cancer patients who received neoadjuvant therapy, sarcopenic patients were
more likely to have a complete pathologic response compared to nonsarcopenic patients [144].
Substantial loss of body weight, adipose tissue and skeletal muscle mass have been reported
among pancreatic cancer patients who received neoadjuvant radiochemotherapy within phase
I and II clinical trials. [145, 146]. Although the resection rate could not be predicted by body
composition parameters (i.e., weight loss, overweight/obesity (pre‐/posttreatment), sarcopenia
with or without overweight/obesity), the extent of skeletal muscle and visceral adipose tissue
loss was negatively associated with disease‐free survival and overall‐ and progression‐free
survival, respectively [145]. Finally, an increasing number of studies show that low skeletal
muscle mass is an independent determinant of chemotherapy toxicity in different patient
populations treated with various chemotherapeutics [147–153]. Chemotherapy toxicity
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frequently leads to dose limitation or abortion of therapy. Consequently, this may lead to less
effective cancer treatment and impaired (disease‐free) survival. Therefore, it is suggested that
it would be better to base dose normalization on skeletal muscle mass rather than body surface
area (BSA), as is commonly performed [147].
3. Identifying the patient with high perioperative risk
3.1. Preoperative assessment
Risk assessment in order to identify patients at risk for postoperative adverse events is a
complex effort. It is made even more difficult by the great variety of primary diseases as well
as comorbidities in surgical oncology patients.
Classically, preoperative risk assessment is based on a complex interaction of the clinician’s
view of the general status of the patient and The consideration of factors such as age, comor‐
bidities and ASA classification. This can be a subjective process and its interpretation can vary
greatly between clinicians. Even the assessment of the ASA classification seems to be a
relatively subjective process [154]. Consultation of an experienced anesthesiologist is often
advised for patients with a compromised physical status (e.g., ASA 3–4) or who are scheduled
to undergo major surgical interventions that can cause physiological derangements.
3.2. Risk factors for adverse outcome
Gastrointestinal surgical oncology patients are often elderly patients. The elderly are at an
increased risk for adverse events and mortality [155, 156]. A patient’s ability to cope with
surgical stressors is determined by a multitude of factors, of which physiological reserves are
the most important. In recent years, improvements have been made to identify more objective
risk factors for adverse outcome after surgery. These include comorbidity classifications,
geriatric frailty assessment, sarcopenia, and malnutrition assessment.
3.3. Comorbidities
Almost all patients who undergo major gastrointestinal surgery have some degree of comor‐
bidity. In order to classify these comorbidities and to determine a risk stratification for
mortality, the Charlson Comorbidity Index (CCI) was introduced [115]. This index was also
used for prediction of mortality risk after complex gastrointestinal surgery in a later study
[157]. In Asian elderly patients (octo‐ and nonagenarians) undergoing surgery for gastric
cancer, a CCI ≥ 5 was associated with a higher postoperative mortality rate [158]. In another
study in elderly Italian patients who underwent curative surgery for gastric cancer, the
presence of comorbidity and not age was the only independent risk factor for mortality [130].
3.4. Frailty
Assessment of frailty as depicted above can be diverse and often incorporates different
measurement modalities. These include questionnaires on self‐reported health and disability,
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handgrip strength measurements, timed get‐up‐and‐go tests and sometimes blood tests
(hemoglobin, albumin). These measurements make frailty assessment difficult in an outpatient
setting. Therefore, fast and easy to perform screening questionnaires have been developed over
the recent years. Examples include PRISMA‐7, Fried's Frailty criteria, Hopkins Frailty score
and Groningen Frailty Indicator (GFI) [159]. Questionnaires such as the GFI encompass
multiple aspects of frailty, i.e., mobility, physical fitness, vision, hearing, nourishment (i.e.,
unintended weight loss), morbidity (i.e., polypharmacy), and psychosocial status [14]. Despite
the comprehensive nature of these questionnaires, the percentage of patients who are
identified as frail vary strongly between different risk assessment tools (11.6–36.4%) [159].
However, these questionnaires have proved to be very useful to identify patients who are at
risk for the development of postoperative adverse events. In gastric cancer patients, a GFI ≥3
was associated with postoperative mortality and morbidity (severe complications) [160]. Frail
patients had an in‐hospital mortality of 23.3% compared to 5.2% for nonfrail patients. Scores
higher than 7 on the Edmonton Frail scale were associated with increased complications after
non‐cardiac surgery (OR 5.02, 95% CI 1.55–16.25) [121]. In another study, Fried's Frailty criteria
were associated with increased complications after major, oncological and urological surger‐
ies [118]. Geriatric assessment using several questionnaires was used in a study and showed
that frailty is an independent risk factor for impaired 1‐year and 5‐year survival after colorectal
cancer surgery [161].
In conclusion, frailty screening and assessment with referral to a geriatric specialist should be
included in preoperative work‐up and shared decision making in elderly patients scheduled
to undergo gastrointestinal surgery for cancer.
3.5. Sarcopenia
A decline in muscle mass, or sarcopenia, is a phenomenon within the process of human aging
but is also part of the cachexia syndrome [127, 162]. Sarcopenia is a complex syndrome and
multiple factors have been identified that contribute to its development [163]. Inadequate
nutrition (low protein intake and impaired metabolism) and inactivity are important contri‐
buting elements, as well as age‐related and possibly endocrine factors [127].
The assessment of sarcopenia is performed by measuring muscle surface areas on abdominal
CT‐scans. At a designated level (e.g., transverse processes of lumbar spine L3), total psoas
cross‐sectional area or total muscle surface area are measured and corrected for patient height,
resulting in an L3‐index (see Figure 2). These measurements can be performed in a semiauto‐
mated fashion by the use of image analysis software. Sex and body mass index (BMI) specific
cutoffs are available to define sarcopenia. For instance: for men 43 cm2/m2 (BMI < 25.0 kg/m2)
and 53 cm2/m2 (BMI ≥ 25.0 kg/m2), in women L3‐index lower than 41 cm2/m2 [164].
Sarcopenia, as measured by low muscle mass CT‐scans, is used in a multitude of studies and
has been shown to be associated with adverse outcome. However, in 2010, the European
Working Group on Sarcopenia in Older People (EWGSOP) defined sarcopenia as a low muscle
mass in combination with either low muscle strength or low physical activity [127]. The
EWGSOP defines low muscle mass as only symptom as presarcopenia.
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3.6. Malnutrition
An imbalance in energy expenditure and nutritional intake is the fundamental physiological
derangement that causes cancer‐induced weight loss. Tumor‐related factors that contribute to
weight loss include early satiety, obstruction complaints, but also tumor induced metabolic
changes [162]. Especially, upper GI cancer patients are at risk for malnutrition, for example, in
31‐43% of gastric cancer patients there can be a weight loss of >10% in the last 6 months. [165].
Malnutrition is a well‐known risk factor for adverse outcomes after upper GI surgery, including
interventions for esophageal, gastric cancer, liver and pancreatic cancer [162, 166, 167].
Figure 1. Short Nutritional Assessment Questionnaire (SNAQ) and Malnutrition Universal Screening Tool (MUST).
Partly adapted from Kruizenga et al. [15] and Rahman et al. [16].
Screening for malnutrition is therefore an important aspect of the preoperative risk assessment
of upper GI cancer patients. Several questionnaires have been developed to screen for malnu‐
trition, which include: NRS‐2002 (nutritional risk screening), MUST (Malnutrition Universal
Screening Tool), SNAQ (Short Nutritional Assessment Questionnaire) [15, 160, 168] (Figure 1).
These tools provide an easy and low‐cost method for nutritional risk stratification and provide
an indication as to when preoperative nutritional interventions are indicated. Patients at risk
for malnutrition should be referred to a dietician for nutritional analysis and supplementation
if needed, in order to optimize preoperative status.
3.7. Patient selection
Upper GI cancer patients are scheduled to undergo major surgery if they are considered “fit
for surgery.” Proper preoperative evaluation can identify avoidable perioperative risks. As
upper GI cancer surgery is often performed in elderly patients, chronic comorbidities are
frequently present.
Basic preoperative assessment, including clinical history taking and physical examination,
should aim at identifying chronic comorbidities. Preoperative evaluation should uncover any
chronic comorbidities, particularly cardiovascular and pulmonary disease [169]. Advice from
other departments should be obtained, e.g., adjustment of pulmonary medications and
Improving Outcome in Gastrointestinal and Hepatopancreaticobiliary Surgical Oncology by Preoperative Risk...
http://dx.doi.org/10.5772/64775
79
corticosteroid supplementation in patients with pulmonary disease. This helps minimizing
avoidable perioperative cardiopulmonary complications.
Another important risk factor for adverse outcome is the presence of diabetes mellitus. This
should therefore be optimally controlled pre‐ and perioperatively. If necessary, referral to a
specialist is recommended.
Referral to a geriatric specialist can be very helpful in the preoperative setting, especially for
frail elderly. Advice can be obtained in the perioperative stage on prevention of delirium, and
of physical and cognitive decline.
Exercise tolerance is also an important aspect to judge physiological reserves. It is most often
determined by the patient’s cardiopulmonary limitations. Metabolic equivalents of a task
(MET) can be helpful with assessing exercise tolerance. Patients who are able to perform four
MET's or greater are regarded to have a low risk for perioperative morbidity [169]. Climbing
a flight of stairs roughly equates to four MET's; when patients are able to do so, they are
considered to be fit for elective surgery.
When patients are adequately evaluated, risks can be communicated between treating
physicians, patients and family members. If the patient is deemed fit for surgery, these
preoperative consultations help provide an optimal perioperative environment for patients
and minimize the risk of preventable complications.
4. Standardized care by the use of clinical pathways
An increasing number of surgical procedures are performed each year for abdominal malig‐
nant diseases. The indications for surgery are expanding and the surgical techniques are
becoming more sophisticated. However, surgical morbidity remains high, especially after
major abdominal surgery such as gastric, esophageal, liver, pancreatic or colorectal surgery.
There is an increasing need for protocoled care and new care pathways for surgery to reduce
surgical impact and perioperative morbidity [170].
Since the last decade of the twentieth century, fast‐track or enhanced recovery care protocols
for surgical care gained popularity. These clinical pathways are aimed at reducing surgical
morbidity by reducing the perioperative physiological and psychological stress and enhancing
patients’ recovery (see Figure 2) [171, 172]. The physiological changes a patient must endure
during and after surgery are influenced by many different factors. Therefore, enhanced
recovery pathways are aimed at a multimodal approach in which the surgeon, anesthesiologist,
nurse, nutritionist, and physiotherapist all contribute in improving the patient’s recovery [173–
175].
As mentioned before, the surgical stress is influenced by many factors, such as the surgical
procedure itself, intraoperative hypothermia, low glucose levels due to perioperative fasting,
intraoperative anesthetics, pain, and being bedridden. These stressors are specific targets for
enhanced recovery pathways. The key elements in enhanced recovery pathways are mini‐
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mized preoperative fasting, limited use of incisions, catheters, and drains, early resumption
of oral diet, early mobilization after surgery and optimal pain control using patient controlled
(epidural) analgesia [170, 173, 174, 176–178].
These elements relieve patients of previously described stressors that are the cause of postop‐
erative morbidity and delayed recovery. The result of enhanced recovery pathways can be seen
in a reduction of postoperative complications and subsequently a shortening of median
hospital stay [179–181].
Figure 2. Important elements of enhanced care protocols for perioperative care.
4.1. Upper GI surgery
4.1.1. Standardized postoperative care
A number of general enhanced recovery pathways developed for colorectal cancer are also
applicable to esophageogastric surgery patients. Aspects that will be discussed in this section
are preoperative nutrition, timing of postoperative oral intake, use of nasogastric and decom‐
pression catheters, early mobilization, and urinary catheter use.
As stated before, malnutrition is associated with adverse outcome in esophagogastric surgery
[182, 183]. Although evidence for preoperative feeding interventions is limited [184], it is still
recommended to screen for and treat malnutrition in gastroesophageal cancer patients by
optimization of nutritional intake with oral feeding supplements [178, 185]. Dietary interven‐
tions have not shown to be beneficial in patients who do not suffer from malnutrition [186].
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Nasogastric decompression recommendations during the postoperative phase are different
after gastric and esophageal surgery. Evidence against nasogastric decompression after
gastrectomy is strong, as several meta‐analyses show deleterious effects of routine nasogastric
tube placement [187, 188]. Furthermore, its routine use does not reduce surgical morbidity.
Additionally, patients without decompression have fewer pulmonary complications, earlier
passage of flatus, earlier resumption of oral intake, and a shorter length of stay [188].
In patients undergoing esophagectomy, in contrast to gastrectomy patients, gastric conduit
decompression is recommended. The aim of the nasogastric tube is to prevent gastric stasis,
pain, vomiting, and aspiration. On the other hand, nasogastric tubes are associated with
increased epistaxis, dislodgement of the catheter, and pulmonary infections [189]. One RCT
that studied the effect of nasogastric tube decompression, however, found a reduction in
pulmonary complications [190]. All in all, gastric conduit decompression via nasogastric tube
is recommended [185].
Timing of resumption of oral diet is challenging after gastrectomy and esophagectomy with
important differences between the two. After gastrectomy, there is evidence to support early
resumption of liquid intake (the first day following surgery) and to further increase this
according to tolerance, starting with light food on day two [178]. Conversely, there are no
studies that report adverse outcome after early and patient controlled introduction of oral diet
in gastrectomy patients [178].
Resumption of oral intake after esophagectomy is somewhat unclear and traditionally
conservative. There are some studies that have investigated early oral intake after gastric and
gastroesophageal resection [191, 192]. After total gastrectomy (n = 77) and esophagectomy (n
= 2), earlier discharge was seen in the enteral feeding group [192]. However, no esophagectomy‐
specific studies have been published on this subject, which makes it difficult to give evidence‐
based recommendations.
After esophagogastric surgery, nutritional support is indicated if 60% of desired oral intake is
not achieved by the end of the first week, as is suggested by a large review [162]. High‐energy
oral sip feeds is the preferred method, but enteral tube feeding can be used when this is not
possible.
Strong evidence exists that bed rest is associated with several adverse outcomes. For example,
even in healthy individuals, bed rest has been shown to decrease maximal oxygen uptake (VO2
max) [193]. Despite this, very few specific postoperative protocols have been developed with
good evidence‐based support [194]. Nonetheless, early postoperative mobilization from day
one, which can be supported by written day‐to‐day patient instructions, is regarded as good
practice [178, 185]. Adequate analgesia is a requirement for effective early mobilization.
Urinary catheters are often used for patients monitoring, especially in the early postoperative
stage. However, there are some notable disadvantages for the use of catheters, including
restricted patient mobility and an increased risk of urinary tract infection. Furthermore, they
have shown to be a predictor for longer length of stay [195]. Transurethral catheters can and
should be removed on day one or two postoperatively if the presence of the catheter is not
required for monitoring [178].
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In conclusion, many aspects of enhanced recovery pathways can be implemented in upper GI
surgery. However, there are some points specific to upper GI that require special attention.
These include the use of nasogastric tubes, early mobilization, timing of resumption of oral
diet, and use of urinary catheters. These points are generally not well studied but recommen‐
dations for daily practice can be made using the available evidence as outlined above.
4.2. Colorectal surgery
4.2.1. Colorectal surgery
Colorectal carcinoma (CRC) is the fourth most common cancer worldwide for both males and
females. Surgery remains an important aspect of curative treatment of CRC, and also the
patient in the palliative setting is frequently operated on due to the obstructive nature of the
disease. Perioperative care for patients undergoing colorectal surgery has improved signifi‐
cantly over the past decades, mainly due to the introduction of enhanced recovery pathways
and the implementation of less invasive surgical techniques. It has been shown that these
programs have a positive influence on the duration of the hospital admission and overall
complication rate [196].
The recommendations that are supported by grade A evidence will be further elucidated in
this section. Furthermore, recommendations that require further high quality research will be
mentioned here as well.
Preoperative preparation of the patient includes fasting protocols and mechanical bowel
preparation. Recent guidelines have altered the traditional nil by mouth period (fasting from
midnight) to a minimum period of two hours, based on a high‐quality meta‐analysis [197]. It
has been shown that prolonged fasting before surgery does not increase the pH of gastric
content nor does it influence the aspiration risk during and after surgery.
Mechanical bowel preparation (MBP) has been used in combination with oral antibiotic
therapy since the 70’s to decrease the bacterial load in the bowel lumen prior to surgery.
However, from the many studies have been conducted since, no convincing evidence arose
regarding the beneficial effects of MBP alone, which in part explains why MBP has been
abandoned in many institutions. In fact, several articles described possible harmful effects
associated with mechanically cleansing the bowel, such as prolonged postoperative ileus and
spillage of bowel content into the abdominal cavity [198]. However, none of these studies
included an arm where a combination of MBP and oral antibiotics was compared to MBP and
oral antibiotics alone. Furthermore, several studies have shown a reduced length of stay and
lower risk of surgical site infection when patients were subjected to both oral and mechanical
bowel preparation [199, 200].
Another important change that has been observed in daily practice is the intravenous admin‐
istration of antibiotics as opposed to oral administration, mostly because of practical reasons.
A recently conducted Cochrane Review has focused on the timing, type and administration
route of antibiotic prophylaxis and, but concluded that robust evidence on this is still lacking
[201]. It seems that a combination of oral and intravenous prophylaxis is most effective in
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decreasing the risk of surgical site infection, as are antibiotics that cover both aerobic and
anaerobic bacteria [201]. For intravenous antibiotics, it is generally accepted that the optimal
timing of administration is 30–60 min before surgery [202]. No recommendations can be made
for timing of oral antibiotics based on the available literature.
An important way of reducing the surgical stress is the use of epidural analgesia. It reduces
the use of opioids during the postoperative phase, which in turn provides rapid awakening,
early intake and mobilization, and therefore improves gastrointestinal motility [203]. Besides
the adverse effects on postoperative ileus, important side effects of opioids on the respiratory
function and central nervous system have been described [204]. There is an important lack of
level A evidence against the use of NSAIDs during the postoperative phase. However,
retrospective data and animal studies have shown an increased risk for anastomotic leakage
with the use of NSAIDs [205–207]. It is therefore recommended to refrain from the prescription
of NSAIDs following colorectal surgery.
4.3. HPB surgery
In some centers worldwide that perform hepatopancreatobiliary surgery, similar enhanced
recovery pathways have been implemented as to those that have been described in the previous
sections for gastroesophageal and colorectal surgery. Naturally, there are similarities between
the pathways for gastrointestinal surgery and HPB surgery such as early resumption of oral
intake, early mobilization, the use of laxatives postoperatively and the use of epidural
analgesia [176, 208, 209]. There are, however, a number of important specific considerations
for enhanced care pathways in the field of liver and pancreatic surgery that will be addressed
in this section.
4.3.1. Liver surgery
Laparoscopic surgery is being practiced increasingly more in the field of abdominal sur‐
gery in general and has become the gold standard for many procedures such as the chole‐
cystectomy. Minimal invasive keyhole surgery decreases postoperative morbidity and
facilitates faster recovery after surgery. Minimizing incisions is one of the elements of many
enhanced care pathways for that reason. Due to surgical technical challenges, the laparo‐
scopic approach for liver surgery was introduced later than for gastrointestinal surgery. In
the early period of laparoscopic liver surgery, only minor liver resections were performed,
such as the left lateral sectionectomy [210]. Today, the number of laparoscopic liver surgery
procedures is growing both for minor and major liver resections, yielding promising re‐
sults [211, 212].
Traditionally, the placement of prophylactic intra‐abdominal drains after liver surgery is a
strategy that has been used for the early detection of postresectional hemorrhage and bile
leakage. Intra‐abdominal drains, however, have negative effects as well; they can cause
ascending intra‐abdominal infections and can be uncomfortable for the patient, thereby
delaying postoperative recovery. In this day and age, with improved abilities to perform CT‐
or ultrasound‐guided drainage of intra‐abdominal fluid collections, abdominal drains have
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become obsolete for uncomplicated partial liver resection when regarding the number of
postoperative complications and reinterventions [213]. In some cases, the use of a prophylactic
drain can be advocated, for example, when surgery with vascular or biliary reconstruction is
performed or when, in the case of central liver resection, the risk of a postoperative biloma or
hemorrhage increases [214, 215].
4.3.2. Pancreatic surgery
Pancreatic adenocarcinomas are notorious for causing severe weight loss in patients, and, as
mentioned before, cachexia is an important challenge in this patient group. Therefore, an
optimal preoperative nutritional status is a key element in the enhanced recovery pathways
for pancreatic surgery. Fortunately, the majority of the patients that undergo a pancreatic
resection are not malnourished and have minor to intermediate weight loss. This group does
not need additional nutritional support. However, patients that do suffer from severe weight
loss and are in a state of malnourishment are in need of receiving additional nutrition. This
can be administered either by oral supplements or by enteral tube feeding if necessary [176,
216].
Cholestasis is one of the side effects of pancreatic carcinoma. This occurs when the common
bile duct is obstructed by the tumor mass. Preoperative biliary drainage of the common bile
duct should be considered in severe jaundiced patients. Preoperative biliary drainage can be
performed by the placement of a stent in the common bile duct via endoscopic retrograde
cholangiopancreatography (ERCP). When the common bile duct is inaccessible via ERCP due
to impassable obstruction in the bile duct or duodenum, biliary drainage can be performed via
percutaneous transhepatic cholangiography (PTHC). A serum bilirubin concentration >250
μmol/l is associated with an increased risk of postoperative morbidity. Patients with a higher
serum concentration of bilirubin should therefore receive preoperative biliary drainage [176,
217].
In most enhanced recovery protocols, the routine use of prophylactic abdominal drains after
surgery is discouraged because of drain‐related morbidity. There has been a recent debate on
the routine use of prophylactic abdominal drains after pancreaticoduodenectomy (PD). After
a PD, an abdominal drain is normally placed for early detection of anastomotic leakage or
hemorrhage. Leakages of the pancreaticojejunostomy or the hepaticojejunostomy can have
detrimental effects and are potentially lethal. However, drain‐related complications have also
been reported, and earlier studies with small patient groups showed promising results
regarding postoperative complications in patients that were treated without a prophylactic
abdominal drain [218]. In addition, early drain removal was shown to be beneficial for
postoperative morbidity [219]. In a recent RCT, the abandonment of prophylactic drain use
had a detrimental effect on postoperative mortality. Therefore, prophylactic drain use is still
advised for safe postoperative care after PD in all patients [220, 221]. In the coming years, new
evidence will have to show if the use of prophylactic abdominal drains can be abandoned in
low‐risk patients undergoing a PD.
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4.4. ICU care
4.4.1. Handover
The transfer from the operating theatre to the intensive care unit is the first step in standardized
postoperative care, and should therefore be considered a crucial one. Agarwal et al. report a
substantial improvement in quality of the handover when using a standardized and structured
method of communication in pediatric patients who underwent cardiac surgery. They
compared the knowledge of medical providers regarding patient information following the
handover by means of a questionnaire. The knowledge of the clinical team members after the
structured handover was 92% compared to 69% in case of the verbal handover. Furthermore,
the outcome differences between these two groups were assessed. In the verbal handover
group, 5.4% were in need of cardiopulmonary resuscitation compared to 2.6% in case of the
structured handover (p = 0.043). The same was true for the need of mediastinal re‐exploration:
9% versus 5.5% respectively (p = 0.043). Metabolic acidosis occurred in 6.7% of cases of verbal
handover versus 2.6% structured handover (p = 0.004) and successful early extubation could
be conducted in 43.2% and 50% respectively (p = 0.04). It could therefore be concluded that a
structured handover should be a part of the standardized postoperative care.
4.4.2. Extubation
Early extubation is known to be a predictive factor for early discharge. Cheng et al. already
stated that early extubation led to a decrease of 25% of the total costs of CABG surgery. This
cost reduction is a result of early discharge of the ICU and, consequently, from the hospital
itself. Consequences for the patients are not described in this article but can be imagined. In
cases of intubation, patients are often sedated and immobile. Immobilization induces a
significant decrease in muscle mass and strength. As stated before, the loss of muscle mass
strongly hampers recovery in oncological surgery.
4.4.3. Mobilization
Mobilization is a crucial part of enhanced recovery programs that has been explained earlier
in this chapter. In case of ICU admittance, the patient usually receives cardiovascular support
by means of vasopressin or respiratory support by mechanic ventilation and oxygenation.
Obviously, these conditions make mobilization rather difficult. However, Brahmbhatt et al.
conducted an intervention‐based study in which the intervention group (n = 49) was subjected
to daily interruptions of sedation. Patients in the intervention group received physical and
occupational therapy during the earliest days of critical illness. Outcome parameters were
functional status at hospital discharge, duration of delirium and ventilator‐free days during
the first 28 days. In 29 patients (59%) of the intervention group independent functional status
was reached compared to 19 patients (35%) of the control group (n = 55) (p = 0.02). Furthermore,
a shorter period of delirium (median 2 days) was observed in the intervention group compared
to 4 days in the control group (p = 0.02), as well as a significant increase in ventilator free days:
23.5 versus 21.1 days respectively (p = 0.05).
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4.4.4. Complication management
The intensive care unit uses several instruments to increase insight into risk management. The
most used and internationally recognized are the Simplified Acute Physiologic Score (SAPS),
Sequential Organ Failure Assessment (SOFA), ASA‐score, and Acute Physiology and Chronic
Health Evaluation (APACHE score).
4.4.5. SAPS score
The Simplified Acute Physiologic Score, otherwise known as SAPS, can be used to predict
hospital mortality. Patients with a higher SAPS score have a higher mortality. The latest version
of the SAPS score instrument is SAPS II. SAPS III has also recently been validated. Recent
studies show a good discrimination by SAPS III, but a poor calibration.
4.4.6. SOFA score
The SOFA score consists of six different scores, which are organ specific. These score the
respiratory, nervous, renal, and cardiovascular system, liver and coagulation. Each item can
be scored between one and four, which results in a score between seven and 28.
Figure 3. American Society of Anesthesiologist (ASA) categorization.
4.4.7. ASA classification score
Originally, the ASA physical status classification system was developed by the American
Society of Anesthesiologists and consisted of five categories (see Figure 3). The system was
designed to have a quick method to classify the physical fitness of patients. Later a sixth
category was added.
4.4.8. APACHE score
The APACHE score was originally designed for patients in the intensive care unit. The
designers were trying to develop a quantification method for the severity of disease of ICU‐
admitted patients.
The score is calculated by the use of different parameters: PaO2, temperature, mean arterial
pressure, arterial pH, heart rate, respiratory rate, Glasgow Coma Scale and blood analysis for
sodium, potassium, creatinine, hematocrit, and white blood cell count. All of these measure‐
ments should be conducted in the first 24 hours of admission; the score should not be changed
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during the course of admission. The latest version is the APACHE IV, which has been con‐
structed using a new logistical regression equation, a different set of variables and statistical
modeling to improve accuracy.
5. Improving postoperative outcome
5.1. Cardiopulmonary exercise testing
With expanding indications for surgery and a population that grows increasingly older, patient
selection for extensive surgery becomes more important. To assess if patients are fit for major
abdominal surgery, surgeons and anesthesiologists need objective tools. Cardiopulmonary
exercise testing (CPET) can be used as an objective instrument to assess the cardiopulmonary
fitness of a patient in an outpatient setting.
The test originated from exercise physiology, and was later adopted by other clinical depart‐
ments for the determination of physical condition. Since recent years, different surgical
departments use CPET to objectively assess high‐risk patients before taking the patients to the
operation theatre.
Cardiopulmonary exercise testing is an objective way to assess a patient’s maximal cardiores‐
piratory fitness. CPET is performed on a cycling ergometer or on a treadmill. During the test,
ventilation gas exchange parameters are measured by breath analysis and cardiac parameters
are monitored by electrocardiogram. Ventilation gas analysis is used to determine oxygen and
carbon dioxide exchange. Different protocols can be used for CPET, but cycling ergometry with
an incremental or ‘ramped’ workload is most common [222].
By gradually increasing the workload for the patient, the oxygen demand in the muscles also
increases. When the oxygen demand exceeds oxygen delivery, the anaerobic threshold (AT) is
passed. The AT, together with the maximal or peak oxygen uptake (VO2peak),is valuable
parameters which reflect the maximal cardiopulmonary capacity of a patient [222].
Several CPET‐derived variables have been associated with morbidity, mortality and length of
stay after major intra‐abdominal surgery, in particular the AT and VO2peak. Hence, CPET can
be used to identify patients with decreased cardiopulmonary reserve, which are those patients
who have an increased risk for morbidity and mortality after major intra‐abdominal surgery
[223–225].
Subsequently, patients with an increased perioperative risk based upon low CPET scores can
be offered preoperative exercise therapy or so‐called prehabilitation prior to surgery to
improve their fitness and thereby reducing perioperative risk.
5.2. Prehabilitation/exercise interventions
Prehabilitation and exercise interventions can be applied in frail elderly to reduce the risks of
perioperative morbidity and mortality. The main intention of exercise is to counter the weight
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loss and therefore improve muscle strength and function. This will consequently lead to
improved daily functioning and better quality of life in these patients.
Even though resistance exercise is known to increase muscle strength in older patients, it seems
to have little effect on the actual muscle mass itself. However, several reviews and meta‐
analyses found an improved physical functioning and overall quality of life in cancer patients
from physical exercise [226, 227]. Furthermore, it has been shown that low or decreased
physical functioning in the preoperative phase is associated with postoperative complications
[228, 229].
In addition to the role of exercise, nutritional intake has an important influence on physical
functioning as well. Elderly often have a poor intake, which hampers muscle development and
strengthening. It has been shown that the intake of amino acids combined with physical
exercise elicits the greatest anabolic response [230], and that essential amino acids in particular
stimulate muscle protein synthesis [231]. Beta‐hydroxy‐beta‐methylbutyrate (HMB) has
shown to be a promising effective nutritional supplement in the increase of protein turnover
[232]. When in older men and women HMB supplementation was combined with a resistance
training program, an increase in lean body mass and decrease in body fat was observed, when
compared to the placebo group. [233]. When older men and women were administered
additional nutrition supplements with HMB, their functionality, strength, and lean body mass
improved [234], as did their protein turnover [235]. Other studies have found a positive effect
of whey protein on protein turnover rates when consumed within 1 hour after their exercise
regimen [236].
Recently, the PACES study (Physical exercise during Adjuvant Chemotherapy Effectiveness
Study), experienced beneficial effects from exercise on functionality. In this study, 230 patients
with breast cancer were included and got either a home‐based physical activity program
(Onco‐Move), a moderate to high‐intensity supervised training combined with resistance and
aerobic exercise (OnTrack) or usual care program. Patients with either the Onco‐Move or
OnTrack program showed less decline in their cardiorespiratory fitness and physical func‐
tioning. They also showed less nausea, vomiting and pain during their therapy compared to
the usual care program. Both intervention groups returned to work sooner and worked more
hours per week compared to the control group [237].
As noted before, multiple dimensions can be assessed when evaluating frailty. In addition to
physical parameters, emotional factors and cognition should be assessed as well [238]. Indeed,
psychotherapy has showed to significantly reduce fatigue in patients who were treated for
cancer [239]. Furthermore, interventions with a more general approach, aiming at psycholog‐
ical distress, mood and physical symptoms, are effective in reducing fatigue [240].
5.3. Dietary interventions/optimized nutrition
Malnutrition is very common amongst the hospitalized population as a whole, and the
prevalence increases even further for patients undergoing surgery for upper gastrointestinal
or colorectal malignancies [241, 242]. It has been stated that around 50% of all patients
undergoing surgery for cancer suffer from malnutrition. It is associated with adverse out‐
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comes, including increased morbidity and mortality and decreased quality of life. Further‐
more, it has been shown to be a prognostic indicator for disease specific survival in various
types of cancers [243]. Interestingly, and despite the important impact malnutrition has on
health care costs, the assessment of nutritional status has not yet been implemented in daily
practice [244].
Several factors have been identified that predispose patients to malnutrition, including
anorexia, cachexia and the early satiety sensation frequently experienced by individuals with
cancer. Furthermore, metabolic alterations induced by the presence of the tumor or tumor
factors can compromise nutritional status. An increased inflammatory status, which is often
observed in patients suffering from a malignancy, can trigger a cascade of molecular events,
including increased lipolysis and muscle proteolysis, a syndrome referred to as cancer
cachexia [245]. Cachexia has been especially well described for patients with solid tumors of
the pancreas and upper gastrointestinal tract and less often in patients with lower gastroin‐
testinal cancer.
Clinicians have been aware of the importance of nutritional status for surgical outcome for
over 80 years. Surprisingly, this has not yet led to the development of a generally accepted
screening system for malnourished patients or patients at risk for malnourishment. Several
screening tools have been proposed and validated for this purpose: the nutritional risk index
(NRI), prognostic nutritional index (PNI), subjective global assessment (SGA), malnutrition
universal screening tool (MUST) and short nutritional screening questionnaire (SNAQ) to
name some. These tools, together with certain anthropometric measurements, such as body
mass index (BMI) and serum markers of nutrition (e.g. albumin) can aid in the risk assessment
and the development of a treatment plan. Significant weight loss (>5% of weight loss during
the 6 months prior to surgery) was found to be as a reliable marker for malnutrition as SGA,
MUST and NRS, whilst a low BMI was not [243, 246].
5.3.1. The obesity-paradox
A high BMI is associated with better outcome in cancer patients [247], which is often referred
to as the obesity‐paradox. However, recent studies investigated the hypothesis that adipose
tissue may only have a protective effect in case of abundant muscle tissue, which is often the
case in obesity. In order to do so, muscle mass, fat mass and BMI were measured in patients
undergoing surgery for a malignancy. Indeed, a high BMI (>25) was associated with a longer
overall survival. However, the shortest survival was observed in patients with a relatively high
BMI but with a low muscle mass, i.e. in patients with sarcopenic obesity [248].
6. Conclusion
Surgery for cancer of the alimentary tract involves extensive and complex procedures. These
surgical procedures have improved in the last decades; new techniques and treatment options
have broadened the field of surgical oncology for abdominal cancers. Despite this improve‐
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ment, the postoperative outcome, in terms of postoperative morbidity, remains a significant
issue for the patient and the physician.
One of the biggest challenges, in regard to postoperative outcome, is the aging population that
undergoes surgery for cancer. Functional compromise, defined by several conditions such as
fatigue, sarcopenia, cachexia, malnutrition, the presence of comorbidities and frailty, is
especially common in the elderly patient, making them more susceptible to surgical stressors.
Several screening tools have been developed to assess the presence of these conditions in order
to identify avoidable perioperative risks.
There is an increasing need for protocoled care and new care pathways to reduce perioperative
morbidity. The introduction of fast-track and enhanced recovery programs has led to a faster
patient recovery and a reduction of complications after abdominal surgery. These care
programs are aimed at reducing the surgical stressors. General principles of such programs
are: minimized preoperative fasting, limited use of incisions, catheters and drains, early
resumption of diet and early mobilization after surgery and optimal pain control. In addition,
every type of surgery has its specific recommendations for protocoled care.
A multimodal approach is recommended when planning surgery for a compromised patient,
including control of chronic diseases, referral to a geriatric specialist and optimizing nutritional
status and exercise tolerance. Cardiopulmonary exercise testing can be used before surgery to
determine the patient’s cardiorespiratory fitness. Subsequently, exercise interventions before
treatment can be used in cancer patients with a poor cardiorespiratory fitness to improve the
treatment results. Regarding the nutritional status, this can be compromised due to cancer-
related anorexia and cachexia. Preoperative assessment of the nutritional status should be
considered, as malnourishment can have a negative effect on the postoperative outcome.
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